Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis: a Recent Review

doi:10.12114/j.issn.1007-9572.2022.0327

Chinese General Practice ›› 2023, Vol. 26 ›› Issue (03): 372-379.DOI: 10.12114/j.issn.1007-9572.2022.0327

• Review & Perspectives • Previous Articles Next Articles

Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis: a Recent Review

1.The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450046, China
2.Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
3.Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan Province & Education Ministry of P.R.China, Henan University of Chinese Medicine, Zhengzhou 450046, China

Received:2022-05-06 Revised:2022-07-22 Published:2023-01-20 Online:2022-06-27
Contact: YU Xueqing
About author:
XU L L, HONG Y Z, LI Z H, et al. Prognostic biomarkers in idiopathic pulmonary fibrosis: a recent review [J] .Chinese General Practice, 2023, 26 (3) : 372-379.

特发性肺纤维化预后标志物的研究进展

1．450046　河南省郑州市，河南中医药大学第一临床医学院
2．450000　河南省郑州市，河南中医药大学第一附属医院呼吸与危重症医学科
3．450046　河南省郑州市，河南中医药大学呼吸疾病中医药防治省部共建协同创新中心

通讯作者: 余学庆
作者简介:
徐莉莉，洪赟晢，李智慧，等.特发性肺纤维化预后标志物的研究进展[J].中国全科医学，2023，26（3）：372-379.[www.chinagp.net] 作者贡献：徐莉莉、余学庆负责文章的构思与设计，对文章整体负责，监督管理；徐莉莉制定检索策略并撰写论文；洪赟晢、李智慧、于宁霞负责文献检索和整理；洪赟晢、林青青负责论文修订；邸家琪、杨曙光负责文章的质量控制及审校。
基金资助:
国家自然科学基金面上项目(82174307，81973779); 河南省首批中医药拔尖人才培养项目(2019ZYBJ02)

Abstract

Abstract:

Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial lung disease characterized by rapid progression, poor prognosis, and short median survival, seriously endangering patients' health. Early accurate prediction of the prognosis is an important part of the diagnosis and management process of IPF, which is conducive to the improvement of management and prognosis in IPF. A growing number of prognostic biomarkers for IPF have been discovered recently, and those with a high prognostic value could help to stratify prognostic risks and assess outcomes. We reviewed the latest literature about potential prognostic biomarkers of IPF, involving proteins, genes, microbial colonies and cells, and considered matrix metalloproteinase-7, telomere length and fibrocytes to be more reliable, while the prognostic values of Krebs von den lungen-6, surfactant protein A, and MUC5B promoter single nucleotide polymorphism are controversial and need to be further studied, and those of latent-transforming growth factor β-binding protein-2, angiopoietin-2, TOLLIP promoter SNP and microbial colony remain to be verified due to little evidence. It is hoped that our review could provide a reference for clinical selection of objective indicators for early identifying high-risk patients and timely initiating treatment, as well as future prognostic research on IPF.

Key words: Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Lung diseases, interstitial, Biomarkers, Telomere, Prognosis, Review, Research progress

摘要：

特发性肺纤维化（IPF）是一种纤维化型间质性肺疾病，该疾病进展快、预后差、中位生存期短，严重危害患者健康。在病程早期准确评估IPF患者预后，有助于加强疾病管理、改善患者结局，因此IPF的预后评估是该病诊疗的重要一环。近年来与IPF预后相关的标志物不断涌现，良好的预后标志物能够协助判断IPF患者的危险分层与结局。因此本文从蛋白、基因、微生物菌落、细胞等方面总结了既往研究中发现的IPF可能的预后标志物，提示基质蛋白酶7（MMP-7）、端粒长度（TL）和纤维细胞是较为可靠的IPF预后标志物。涎液化糖链抗原6（KL-6）、表面活性蛋白A（SP-A）、MUC5B基因启动子单核苷酸多态性（SNP）等生物标志物的预后价值存在争议，有待进一步研究。潜在转化生长因子结合蛋白2（LTBP-2）、血管生成素2（Ang-2）、TOLLIP启动子SNP、微生物菌落等预后标志物的研究相对较少，预后作用有待验证。本文能够为临床早期识别高危患者、及时把握干预时机提供更加客观的指标，为今后IPF的预后研究提供参考。

关键词: 特发性肺纤维化, 肺纤维化, 肺疾病, 间质性, 生物标记, 端粒, 预后, 综述, 研究进展

XU Lili,HONG Yunzhe,LI Zhihui, et al. Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis: a Recent Review[J]. Chinese General Practice, 2023, 26(03): 372-379. DOI: 10.12114/j.issn.1007-9572.2022.0327.
徐莉莉,洪赟晢,李智慧等. 特发性肺纤维化预后标志物的研究进展[J]. 中国全科医学, 2023, 26(03): 372-379. DOI: 10.12114/j.issn.1007-9572.2022.0327.

References 81

[1]	LYNCH D A，SVERZELLATI N，TRAVIS W D，et al. Diagnostic criteria for idiopathic pulmonary fibrosis：a Fleischner Society White Paper[J]. Lancet Respir Med，2018，6（2）：138-153. DOI：10.1016/S2213-2600(17)30433-2.
[2]	MAHER T M，BENDSTRUP E，DRON L，et al. Global incidence and prevalence of idiopathic pulmonary fibrosis[J]. Respir Res，2021，22（1）：197. DOI：10.1186/s12931-021-01791-z.
[3]	COTTIN V，SCHMIDT A，CATELLA L，et al. Burden of idiopathic pulmonary fibrosis progression：a 5-year longitudinal follow-up study[J]. PLoS One，2017，12（1）：e0166462. DOI：10.1371/journal.pone.0166462.
[4]	XUAN J W，LU Y J，REN M D，et al. Direct economic burden of idiopathic pulmonary fibrosis in China[J]. China Journal of Pharmaceutical Economics，2019，14（6）：9-12. DOI：10.12010/j.issn.1673-5846.2019.06.002.
[5]	STRONGMAN H，KAUSAR I，MAHER T M. Incidence，prevalence，and survival of patients with idiopathic pulmonary fibrosis in the UK[J]. Adv Ther，2018，35（5）：724-736. DOI：10.1007/s12325-018-0693-1.
[6]	李炯. 特发性肺纤维化病情评估和预后生物标志物的研究进展[J]. 重庆医学，2017，46（25）：3591-3594. DOI：10.3969/j.issn.1671-8348.2017.25.045.
[7]	袁殷茹，张敏. 特发性肺纤维化预后相关生物标志物的研究进展[J]. 中国医药导报，2017，14（5）：31-34.
[8]	王慧选，徐敏纹，鹿莉，等. 间质性肺病小鼠循环纤维细胞与血清KL-6的相关性[J]. 中国老年学杂志，2019，39（21）：5336-5339. DOI：10.3969/j.issn.1005-9202.2019.21.060.
[9]	ISHIKAWA N，HATTORI N，YOKOYAMA A，et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig，2012，50（1）：3-13. DOI：10.1016/j.resinv.2012.02.001.
[10]	SUN D，CHENG Z，JIANG T C，et al. Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF[J]. National Medical Journal of China，2020，100（10）：748-752. DOI：10.3760/cma.j.cn112137-20191008-02166.
[11]	WAKAMATSU K，NAGATA N，KUMAZOE H，et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis[J]. Respir Investig，2017，55（1）：16-23. DOI：10.1016/j.resinv.2016.09.003.
[12]	HUANG T H，KUO C W，CHEN C W，et al. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib：a retrospective real-world cohort study[J]. BMC Pulm Med，2021，21（1）：165. DOI：10.1186/s12890-021-01530-6.
[13]	ALOISIO E，BRAGA F，PURICELLI C，et al. Prognostic role of Krebs von den Lungen-6（KL-6）measurement in idiopathic pulmonary fibrosis：a systematic review and meta-analysis[J]. Clin Chem Lab Med，2021，59（8）：1400-1408. DOI：10.1515/cclm-2021-0199.
[14]	HAMAI K，IWAMOTO H，ISHIKAWA N，et al. Comparative study of circulating MMP-7，CCL18，KL-6，SP-A，and SP-D as disease markers of idiopathic pulmonary fibrosis[J]. Dis Markers，2016，2016：4759040. DOI：10.1155/2016/4759040.
[15]	D'ALESSANDRO M，BERGANTINI L，CAMELI P，et al. Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy[J]. Cancers（Basel），2021，13（4）：689. DOI：10.3390/cancers13040689.
[16]	周益民，杜晓敏. 肺表面活性物质SP-A和SP-D免疫调节机制研究进展[J]. 中国预防兽医学报，2020，42（12）：1296-1301. DOI：10.3969/j.issn.1008-0589.202005020.
[17]	GREENE K E，KING T E Jr，KUROKI Y，et al. Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis[J]. Eur Respir J，2002，19（3）：439-446. DOI：10.1183/09031936.02.00081102.
[18]	WANG K，JU Q，CAO J，et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis：a systematic review and meta-analysis[J]. Medicine（Baltimore），2017，96（23）：e7083. DOI：10.1097/MD.0000000000007083.
[19]	TAKAHASHI H，SHIRATORI M，KANAI A，et al. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D[J]. Respirology，2006，11（Suppl）：S51-54. DOI：10.1111/j.1440-1843.2006.00809.x.
[20]	KINDER B W，BROWN K K，MCCORMACK F X，et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis[J]. Chest，2009，135（6）：1557-1563. DOI：10.1378/chest.08-2209.
[21]	TODD J L，VINISKO R，LIU Y，et al. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort[J]. BMC Pulm Med，2020，20（1）：64. DOI：10.1186/s12890-020-1103-4.
[22]	RICHARDS T J，KAMINSKI N，BARIBAUD F，et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med，2012，185（1）：67-76. DOI：10.1164/rccm.201101-0058OC.
[23]	SONG J W，DO K H，JANG S J，et al. Blood biomarkers MMP-7 and SP-A：predictors of outcome in idiopathic pulmonary fibrosis[J]. Chest，2013，143（5）：1422-1429. DOI：10.1378/chest.11-2735.
[24]	TZOUVELEKIS A，HERAZO-MAYA J D，SLADE M，et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis[J]. Respirology，2017，22（3）：486-493. DOI：10.1111/resp.12920.
[25]	BAUER Y，WHITE E S，DE BERNARD S，et al. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis[J]. ERJ Open Res，2017，3（1）：00074-02016. DOI：10.1183/23120541.00074-2016.
[26]	SOKAI A，HANDA T，TANIZAWA K，et al. Matrix metalloproteinase-10：a novel biomarker for idiopathic pulmonary fibrosis[J]. Respir Res，2015，16：120. DOI：10.1186/s12931-015-0280-9.
[27]	LIAO Y，QI X L，CAO Y，et al. Elevations in the levels of NF-κB and inflammatory chemotactic factors in the brains with Alzheimer's disease - one mechanism may involve α3 nicotinic acetylcholine receptor[J]. Curr Alzheimer Res，2016，13（11）：1290-1301. DOI：10.2174/1567205013666160703174254.
[28]	廖明星，潘瑞琪，艾承锦，等. 肺纤维化血清KL-6、TGF-β、CXCL13水平与病变程度的关系及其联合预测价值[J]. 医学研究生学报，2021，34（1）：62-67. DOI：10.16571/j.cnki.1008-8199.2021.01.012.
[29]	XUE J M，KASS D J，BON J，et al. Plasma B lymphocyte Stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients[J]. J Immunol，2013，191（5）：2089-2095. DOI：10.4049/jimmunol.1203476.
[30]	VUGA L J，TEDROW J R，PANDIT K V，et al. C-X-C motif chemokine 13（CXCL13）is a prognostic biomarker of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med，2014，189（8）：966-974. DOI：10.1164/rccm.201309-1592OC.
[31]	GUO L，YANG Y，LIU F，et al. Clinical research on prognostic evaluation of subjects with IPF by peripheral blood biomarkers，quantitative imaging characteristics and pulmonary function parameters[J]. Arch Bronconeumol（Engl Ed），2020，56（6）：365-372. DOI：10.1016/j.arbres.2019.08.020.
[32]	PRASSE A，PROBST C，BARGAGLI E，et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med，2009，179（8）：717-723. DOI：10.1164/rccm.200808-1201OC.
[33]	JIA J，DEPIANTO D，ABBAS A R，et al. P022 Assessing the prognostic performance of CCL18，MMP7，YKL40 and periostin in bronchoalveolar lavage and peripheral blood in idiopathic pulmonary fibrosis[J]. QJM，2016，109（suppl_1）：S29. DOI：10.1093/qjmed/hcw119.026.
[34]	CALISKAN C，JGER B，TERWOLBECK O，et al. Serum CCL18 levels predict survival and disease progression in IPF patients treated with antifibrotic drugs[J]. Pneumologie，2019，73（2）：112-113. DOI：10.1055/s-0039-1678394.
[35]	NEIGHBORS M，CABANSKI C R，RAMALINGAM T R，et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone：post-hoc assessment of the CAPACITY and ASCEND trials[J]. Lancet Respir Med，2018，6（8）：615-626. DOI：10.1016/S2213-2600(18)30185-1.
[36]	SIDEEK M A，SMITH J，MENZ C，et al. A central bioactive region of LTBP-2 stimulates the expression of TGF-β1 in fibroblasts via Akt and p38 signalling pathways[J]. Int J Mol Sci，2017，18（10）：E2114. DOI：10.3390/ijms18102114.
[37]	SURI F，YAZDANI S，ELAHI E. LTBP2 knockdown and oxidative stress affect glaucoma features including TGFβ pathways，ECM genes expression and apoptosis in trabecular meshwork cells[J]. Gene，2018，673：70-81. DOI：10.1016/j.gene.2018.06.038.
[38]	ENOMOTO Y，MATSUSHIMA S，SHIBATA K，et al. LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis[J]. Clin Sci（Lond），2018，132（14）：1565-1580. DOI：10.1042/CS20180435.
[39]	张致苍，雷尚昆. 血清LTBP2作为特发性肺纤维化患者预后标志物的研究[J]. 中华肺部疾病杂志（电子版），2019，12（6）：733-737. DOI：10.3877/cma.j.issn.1674-6902.2019.06.013.
[40]	丁丽丽，蔡暖暖，陈丽瑾，等. 血清HMGB1、LTBP2、AGE/RAGEs水平与特发性肺纤维化患者肺功能及预后的关系[J]. 疑难病杂志，2021，20（5）：470-475. DOI：10.3969/j.issn.1671-6450.2021.05.008.
[41]	SATTAR Z，LORA A，JUNDI B，et al. The S100 protein family as players and therapeutic targets in pulmonary diseases[J]. Pulm Med，2021，2021：5488591. DOI：10.1155/2021/5488591.
[42]	LI Y N，BAO J，BIAN Y Y，et al. S100A4+ macrophages are necessary for pulmonary fibrosis by activating lung fibroblasts[J]. Front Immunol，2018，9：1776. DOI：10.3389/fimmu.2018.01776.
[43]	LEE J U，CHANG H S，SHIM E Y，et al. The S100 calcium-binding protein A4 level is elevated in the lungs of patients with idiopathic pulmonary fibrosis[J]. Respir Med，2020，171：105945. DOI：10.1016/j.rmed.2020.105945.
[44]	AKIYAMA N，HOZUMI H，ISAYAMA T，et al. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis[J]. Respirology，2020，25（7）：743-749. DOI：10.1111/resp.13707.
[45]	HESSELSTRAND R，WILDT M，BOZOVIC G，et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis[J]. Respir Med，2013，107（7）：1079-1086. DOI：10.1016/j.rmed.2013.03.015.
[46]	HARA A，SAKAMOTO N，ISHIMATSU Y，et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis[J]. Respir Med，2012，106（4）：571-580. DOI：10.1016/j.rmed.2011.12.010.
[47]	BENNETT D，SALVINI M，FUI A，et al. Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP[J]. Inflammation，2019，42（2）：463-470. DOI：10.1007/s10753-018-00955-2.
[48]	MACHAHUA C，GULER S A，HORN M P，et al. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis：a cross-sectional study in two independent cohorts[J]. BMJ Open Respir Res，2021，8（1）：e000827. DOI：10.1136/bmjresp-2020-000827.
[49]	SHENDEROV K，COLLINS S L，POWELL J D，et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis[J]. J Clin Invest，2021，131（2）：143226. DOI：10.1172/JCI143226.
[50]	LI Y P，HE Y W，CHEN S B，et al. S100A12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis[J]. Front Immunol，2022，13：810338. DOI：10.3389/fimmu.2022.810338.
[51]	LOMAS-NEIRA J，VENET F，CHUNG C S，et al. Neutrophil-endothelial interactions mediate angiopoietin-2-associated pulmonary endothelial cell dysfunction in indirect acute lung injury in mice[J]. Am J Respir Cell Mol Biol，2014，50（1）：193-200. DOI：10.1165/rcmb.2013-0148OC.
[52]	UEHARA M，ENOMOTO N，MIKAMO M，et al. Impact of angiopoietin-1 and-2 on clinical course of idiopathic pulmonary fibrosis[J]. Respir Med，2016，114：18-26. DOI：10.1016/j.rmed.2016.03.001.
[53]	白艳玲，朱海燕，孙启玉，等. 血管生成素对特发性肺纤维化预后的预测价值[J]. 中华危重病急救医学，2017，29（9）：789-793. DOI：10.3760/cma.j.issn.2095-4352.2017.09.005.
[54]	HANCOCK L A，HENNESSY C E，SOLOMON G M，et al. Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice[J]. Nat Commun，2018，9（1）：5363. DOI：10.1038/s41467-018-07768-9.
[55]	WANG H，ZHUANG Y，PENG H，et al. The relationship between MUC5B promoter，TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort[J]. Sci Rep，2019，9（1）：15307. DOI：10.1038/s41598-019-51902-6.
[56]	宋永娜，王林纳，翟建霞，等. MUC5B启动子rs35705950、rs868903基因多态性与特发性肺纤维化的相关性研究[J]. 临床肺科杂志，2021，26（5）：682-686. DOI：10.3969/j.issn.1009-6663.2021.05.008.
[57]	JIANG H M，HU Y J，SHANG L，et al. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis[J]. Int J Clin Exp Pathol，2015，8（11）：14953-14958.
[58]	郭璐，钟振东，刘晓姝，等. MUC5B和TOLLIP基因多态性对特发性肺纤维化患者预后评估的临床研究[J]. 中国呼吸与危重监护杂志，2019，18（6）：543-548. DOI：10.7507/1671-6205.201811081.
[59]	PELJTO A L，ZHANG Y Z，FINGERLIN T E，et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis[J]. JAMA，2013，309（21）：2232-2239. DOI：10.1001/jama.2013.5827.
[60]	BIONDINI D，COCCONCELLI E，BERNARDINELLO N，et al. Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis（IPF）on antifibrotic treatment[J]. Respir Res，2021，22（1）：98. DOI：10.1186/s12931-021-01694-z.
[61]	NOTH I，ZHANG Y Z，MA S F，et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality：a genome-wide association study[J]. Lancet Respir Med，2013，1（4）：309-317. DOI：10.1016/S2213-2600(13)70045-6.
[62]	STERCLOVA M，KISHORE A，SIKOROVA K，et al. Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment[J]. Biomed Rep，2021，15（5）：87. DOI：10.3892/br.2021.1463.
[63]	BONELLA F，CAMPO I，ZORZETTO M，et al. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms（SNPs）in the management of patients with IPF[J]. Orphanet J Rare Dis，2021，16（1）：111. DOI：10.1186/s13023-021-01750-3.
[64]	MOLINA-MOLINA M，PLANAS-CEREZALES L，PERONA R. Telomere shortening in idiopathic pulmonary fibrosis[J]. Arch Bronconeumol（Engl Ed），2018，54（1）：3-4. DOI：10.1016/j.arbres.2017.07.026.
[65]	CAIRNEY C J，KEITH W N. Telomerase redefined：integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity[J]. Biochimie，2008，90（1）：13-23. DOI：10.1016/j.biochi.2007.07.025.
[66]	ARMANIOS M. Telomeres and age-related disease：how telomere biology informs clinical paradigms[J]. J Clin Invest，2013，123（3）：996-1002. DOI：10.1172/JCI66370.
[67]	STUART B D，LEE J S，KOZLITINA J，et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis：an observational cohort study with independent validation[J]. Lancet Respir Med，2014，2（7）：557-565. DOI：10.1016/S2213-2600(14)70124-9.
[68]	DAI J H，CAI H R，LI H，et al.Association between telomere length and survival in patients with idiopathic pulmonary fibrosis[J]. Respirology，2015，20（6）：947-952. DOI：10.1111/resp.12566.
[69]	WANG H，ZHUANG Y，PENG H，et al. The relationship between MUC5B promoter，TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort[J]. Sci Rep，2019，9（1）：15307. DOI：10.1038/s41598-019-51902-6.
[70]	SNETSELAAR R，VAN BATENBURG A A，VAN OOSTERHOUT M F M，et al. Short telomere length in IPF lung associates with fibrotic lesions and predicts survival[J]. PLoS One，2017，12（12）：e0189467. DOI：10.1371/journal.pone.0189467.
[71]	ZHENG C M，ZHAN X，YANG Y H，et al. A rare missense variant in telomerase reverse transcriptase is associated with idiopathic pulmonary fibrosis in a Chinese Han family[J]. Chin Med J（Engl），2018，131（18）：2205-2209. DOI：10.4103/0366-6999.240802.
[72]	ARMANIOS M Y，CHEN J J，COGAN J D，et al. Telomerase mutations in families with idiopathic pulmonary fibrosis[J]. N Engl J Med，2007，356（13）：1317-1326. DOI：10.1056/NEJMoa066157.
[73]	HAN M K，ZHOU Y R，MURRAY S，et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis：an analysis of the COMET study[J]. Lancet Respir Med，2014，2（7）：548-556. DOI：10.1016/S2213-2600(14)70069-4.
[74]	陈存荣，杨婷，许志辉，等. 肺部微生物组成与特发性肺纤维化生存率相关性研究[J]. 中国微生态学杂志，2018，30（12）：1444-1447. DOI：10.13381/j.cnki.cjm.201812018.
[75]	TAKAHASHI Y，SAITO A，CHIBA H，et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis[J]. Respir Res，2018，19（1）：34. DOI：10.1186/s12931-018-0736-9.
[76]	MOLYNEAUX P L，WILLIS-OWEN S A G，COX M J，et al. Host-microbial interactions in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med，2017，195（12）：1640-1650. DOI：10.1164/rccm.201607-1408OC.
[77]	BUCALA R，SPIEGEL L A，CHESNEY J，et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair[J]. Mol Med，1994，1（1）：71-81.
[78]	QUAN T E，COWPER S E，BUCALA R. The role of circulating fibrocytes in fibrosis[J]. Curr Rheumatol Rep，2006，8（2）：145-150. DOI：10.1007/s11926-006-0055-x.
[79]	HEUKELS P，VAN HULST J A C，VAN NIMWEGEN M，et al. Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis[J]. Respir Res，2018，19（1）：90. DOI：10.1186/s12931-018-0798-8.
[80]	MOELLER A，GILPIN S E，ASK K，et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med，2009，179（7）：588-594. DOI：10.1164/rccm.200810-1534OC.
[81]	STEWART I D，NANJI H，FIGUEREDO G，et al. Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis[J]. Eur Respir J，2021，58（1）：2100172. DOI：10.1183/13993003.00172-2021.

Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis: a Recent Review

特发性肺纤维化预后标志物的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 81

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[2]	TIAN Chen, LIU Jianing, TIAN Jinhui, GE Long. Living Systematic Reviews: Methods and Processes for Development [J]. Chinese General Practice, 2025, 28(30): 3853-3860.
[3]	LI Ling, LI Yaping, QIAN Shixing, NIE Jing, LU Chunhua, LI Xia. Research on Influencing Factors and Risk Prediction of Cognitive Function in Community-dwelling Middle-aged and Elderly People [J]. Chinese General Practice, 2025, 28(30): 3773-3778.
[4]	XU Yanpeng, HUANG Pe, ZHANG Pingping, LUO Yan, SHI Xiaoqi, WU Liusong, CHEN Yan, HE Zhixu. Expression of β-Adrenergic Receptors in Acute T-cell Lymphoblastic Leukemia and Its Clinical Significance [J]. Chinese General Practice, 2025, 28(27): 3391-3398.
[5]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[6]	HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344.
[7]	YANG Qifen, ZHAO Huiliang, GUO Yongsheng, QU Jinglian. The Impact of the Jagged1/Notch1 Signalling Pathway on Endothelial-mesenchymal Transition in Idiopathic Pulmonary Fibrosis [J]. Chinese General Practice, 2025, 28(25): 3151-3160.
[8]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[9]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[10]	LI Jiaxin, LIU Zhonghui, XIE Shuo, FU Zhifang, SUN Dan, JIAO Hongmei. Trajectory in Biomarkers of Metabolic and Inflammatory States as Early Predictors of Chronic Critical Illness in Aging Patients [J]. Chinese General Practice, 2025, 28(24): 2993-2999.
[11]	LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088.
[12]	XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071.
[13]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.
[14]	ZHOU Lianpeng, LI Weifeng, DONG Xingang, WANG Xiaoyuan. Research Progress on the Role of Copper Homeostasis Regulation Mechanism in Cognition Disorder [J]. Chinese General Practice, 2025, 28(23): 2941-2949.
[15]	CHEN Fei, WANG Jinying, YU Haibo, LI Xin, ZHANG Jiajia, SHEN Man, ZHAN Xiaokai, TANG Ran, FAN Sibin, ZHAO Fengyi, ZHANG Tianyu, HUANG Zhongxia. Significance of Elevated Urinary NGAL, TIM-1, VCAM-1 and Activin A in Patients with New Diagnosed Multiple Myeloma [J]. Chinese General Practice, 2025, 28(22): 2740-2749.